title: No need for constant help: human IgG2 antibodies have an autonomous agonistic activity for immunotherapy of cancer.
abstract: Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human therapy.
authors.affiliation: Institute of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erwin-Rommelstrasse 3, 91058 Erlangen, Germany.
authors.forename: Anja
authors.initials: A
authors.lastname: Lux
authors.affiliation: Institute of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erwin-Rommelstrasse 3, 91058 Erlangen, Germany. Electronic address: falk.nimmerjahn@fau.de.
authors.forename: Falk
authors.initials: F
authors.lastname: Nimmerjahn
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry* / Q000627:therapeutic use*; D017452:Receptors, IgG / Q000276:immunology*; D013945:Thymoma / Q000517:prevention & control*; D013953:Thymus Neoplasms / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D017452:Receptors, IgG